Insider Selling: Teleflex Incorporated (TFX) Director Sells 200 Shares of Stock

Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $276.44, for a total value of $55,288.00. Following the completion of the sale, the director now directly owns 8,080 shares in the company, valued at $2,233,635.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Teleflex Incorporated (NYSE TFX) opened at $272.36 on Friday. The stock has a market capitalization of $12,269.54, a price-to-earnings ratio of 49.70, a PEG ratio of 2.01 and a beta of 1.15. The company has a current ratio of 4.72, a quick ratio of 3.70 and a debt-to-equity ratio of 0.88. Teleflex Incorporated has a 1-year low of $169.15 and a 1-year high of $288.78.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. The firm had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The company’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.80 earnings per share. analysts predict that Teleflex Incorporated will post 8.36 EPS for the current year.

Several equities research analysts have commented on TFX shares. Stephens reissued a “buy” rating and issued a $300.00 target price on shares of Teleflex in a report on Thursday, January 18th. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Piper Jaffray Companies started coverage on Teleflex in a report on Friday, November 10th. They issued an “overweight” rating and a $295.00 target price on the stock. Jefferies Group boosted their target price on Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Finally, Needham & Company LLC boosted their target price on Teleflex from $237.00 to $285.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company’s stock. Teleflex presently has an average rating of “Hold” and an average target price of $283.89.

Several large investors have recently made changes to their positions in the company. Atlanta Capital Management Co. L L C lifted its holdings in shares of Teleflex by 2.6% during the second quarter. Atlanta Capital Management Co. L L C now owns 2,519,464 shares of the medical technology company’s stock valued at $523,444,000 after purchasing an additional 64,985 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Teleflex by 50,429.2% during the second quarter. Janus Henderson Group PLC now owns 1,816,020 shares of the medical technology company’s stock valued at $377,296,000 after purchasing an additional 1,812,426 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Teleflex by 24.1% during the fourth quarter. American Century Companies Inc. now owns 1,474,609 shares of the medical technology company’s stock valued at $366,912,000 after purchasing an additional 286,700 shares in the last quarter. State Street Corp lifted its holdings in shares of Teleflex by 1.8% during the second quarter. State Street Corp now owns 1,399,922 shares of the medical technology company’s stock valued at $290,853,000 after purchasing an additional 25,401 shares in the last quarter. Finally, Koch Industries Inc. lifted its holdings in shares of Teleflex by 47,174.3% during the second quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock valued at $955,000 after purchasing an additional 957,639 shares in the last quarter. 88.85% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://sportsperspectives.com/2018/02/04/insider-selling-teleflex-incorporated-tfx-director-sells-200-shares-of-stock.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply